Affiliation:
1. Department of Pharmacy Birla Institute of Technology and Science‐Pilani, Pilani Campus Pilani Rajasthan India
Abstract
AbstractBackgroundBeing amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β‐catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β‐catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non‐canonical based on β‐catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β‐catenin signalling for CKD management is of utmost relevance.ObjectivesThe primary aim of this review is to highlight the significance of targeting Wnt/β‐catenin signalling for CKD management.MethodsThe literature review regarding the role of Wnt/β‐catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.ResultsThe current review summarises the pharmacological therapies modulating the Wnt/β‐catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.ConclusionWnt/β‐catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β‐catenin signalling have emerged as effective means for alleviating CKD.